Researchers surveyed academic institutions around the country to learn about best practices in shuttering and reactivating research during a pandemic and the processes they used to protect research personnel and participants.
As Colorado surpasses a 47 percent rate of its population being fully immunized (with 12 counties surpassing 70 percent), researchers continue to expand the study of the vaccines on children as young as five years old. The CCTSI's Pediatric Clinical and Translational Research Center (CTRC) is playing a major role as it conducts the Pfizer BioNTech COVID-19 vaccine trial for children ages 5 - 11.
When the pandemic hit last year, the CCTSI responded by creating the COVID-19-Rapid Research Pilot Program. Fifty-five people applied and the CCTSI chose four awardees. More than one year later, read about what they learned.
A new $8.7 million grant from the National Institutes of Health (NIH) will enable researchers to test the real-world effectiveness of a promising treatment for high-risk COVID-19 outpatients and to study the best way to reach the population who is at the greatest risk of serious disease and hospitalization.
This summer, the FDA approved a drug for the treatment of seizures associated with Dravet syndrome, a rare form of epilepsy. The approval comes after years of clinical trials, two of which took place in the CCTSI's CTRC at Children's Hospital Colorado.
NCATS and NIH have launched a National COVID Cohort Collaborative (N3C) to collect electronic health record (EHR) data from partners across the U.S. in a secure cloud-based enclave. CCTSI leader Tell Bennet, MD, plays a key role.